Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 790

1.

Galectin-3 correlates with arrhythmogenic right ventricular cardiomyopathy and predicts the risk of ventricular -arrhythmias in patients with implantable defibrillators.

Oz F, Onur I, Elitok A, Ademoglu E, Altun I, Bilge AK, Adalet K.

Acta Cardiol. 2017 Aug;72(4):453-459. doi: 10.1080/00015385.2017.1335371. Epub 2017 Jul 14.

PMID:
28705047
2.

Personalizing Risk Stratification for Sudden Death in Dilated Cardiomyopathy: The Past, Present, and Future.

Halliday BP, Cleland JGF, Goldberger JJ, Prasad SK.

Circulation. 2017 Jul 11;136(2):215-231. doi: 10.1161/CIRCULATIONAHA.116.027134. Review.

PMID:
28696268
3.

Treatment of Ventricular Arrhythmias and Use of Implantable Cardioverter-Defibrillators to Improve Survival in Older Adult Patients with Cardiac Disease.

Jacobson JT, Iwai S, Aronow WS.

Heart Fail Clin. 2017 Jul;13(3):589-605. doi: 10.1016/j.hfc.2017.02.015. Epub 2017 May 2. Review.

PMID:
28602374
4.

Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators.

Bilchick KC, Wang Y, Cheng A, Curtis JP, Dharmarajan K, Stukenborg GJ, Shadman R, Anand I, Lund LH, Dahlström U, Sartipy U, Maggioni A, Swedberg K, O'Conner C, Levy WC.

J Am Coll Cardiol. 2017 May 30;69(21):2606-2618. doi: 10.1016/j.jacc.2017.03.568.

PMID:
28545633
5.

Disease Severity and Exercise Testing Reduce Subcutaneous Implantable Cardioverter-Defibrillator Left Sternal ECG Screening Success in Hypertrophic Cardiomyopathy.

Srinivasan NT, Patel KH, Qamar K, Taylor A, Bacà M, Providência R, Tome-Esteban M, Elliott PM, Lambiase PD.

Circ Arrhythm Electrophysiol. 2017 Apr;10(4). pii: e004801. doi: 10.1161/CIRCEP.117.004801.

PMID:
28408651
6.

Adding Defibrillation Therapy to Cardiac Resynchronization on the Basis of the Myocardial Substrate.

Barra S, Boveda S, Providência R, Sadoul N, Duehmke R, Reitan C, Borgquist R, Narayanan K, Hidden-Lucet F, Klug D, Defaye P, Gras D, Anselme F, Leclercq C, Hermida JS, Deharo JC, Looi KL, Chow AW, Virdee M, Fynn S, Le Heuzey JY, Marijon E, Agarwal S; French-UK-Sweden CRT Network.

J Am Coll Cardiol. 2017 Apr 4;69(13):1669-1678. doi: 10.1016/j.jacc.2017.01.042.

PMID:
28359511
7.

Ventricular arrhythmias in patients with newly diagnosed nonischemic cardiomyopathy: Insights from the PROLONG study.

Duncker D, König T, Hohmann S, Bauersachs J, Veltmann C.

Clin Cardiol. 2017 Aug;40(8):586-590. doi: 10.1002/clc.22706. Epub 2017 Mar 23.

8.

Cardiac Resynchronization Therapy Reduces Ventricular Arrhythmias in Primary but Not Secondary Prophylactic Implantable Cardioverter Defibrillator Patients: Insight From the Resynchronization in Ambulatory Heart Failure Trial.

Sapp JL, Parkash R, Wells GA, Yetisir E, Gardner MJ, Healey JS, Thibault B, Sterns LD, Birnie D, Nery PB, Sivakumaran S, Essebag V, Dorian P, Tang AS.

Circ Arrhythm Electrophysiol. 2017 Mar;10(3). pii: e004875. doi: 10.1161/CIRCEP.116.004875.

PMID:
28292754
9.

Comparison of Multivariate Risk Estimation Models to Predict Prognosis in Patients With Implantable Cardioverter Defibrillators With or Without Cardiac Resynchronization Therapy.

Akoudad S, Dabiri Abkenari L, Schaer BA, Sticherling C, Levy WC, Jordaens L, Theuns DA.

Am J Cardiol. 2017 May 1;119(9):1414-1420. doi: 10.1016/j.amjcard.2017.01.035. Epub 2017 Feb 10.

PMID:
28267958
10.

Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial.

Robinson VM, Bharucha DB, Mahaffey KW, Dorian P, Kowey PR; SHIELD-2 Investigators.

Am Heart J. 2017 Mar;185:43-51. doi: 10.1016/j.ahj.2016.10.025. Epub 2016 Nov 15.

12.

Arrhythmic risk stratification in heart failure: Time for the next step?

Gatzoulis KA, Sideris A, Kanoupakis E, Sideris S, Nikolaou N, Antoniou CK, Kolettis TM.

Ann Noninvasive Electrocardiol. 2017 Mar;22(2). doi: 10.1111/anec.12430. Epub 2017 Feb 3. Review.

PMID:
28252256
13.

Pattern of initiation of monomorphic ventricular tachycardia and implications on tachycardia mechanism.

Barbosa RS, Glass L, Proietti R, Burstein B, Sobolik L, Zhang ZD, Viart G, Shrier A, Essebag V.

Minerva Cardioangiol. 2017 Aug;65(4):357-368. doi: 10.23736/S0026-4725.17.04351-1. Epub 2017 Feb 27.

PMID:
28240517
14.

Effect of Sleep-Disordered Breathing on Appropriate Implantable Cardioverter-Defibrillator Therapy in Patients With Heart Failure: A Systematic Review and Meta-Analysis.

Kwon Y, Koene RJ, Kwon O, Kealhofer JV, Adabag S, Duval S.

Circ Arrhythm Electrophysiol. 2017 Feb;10(2):e004609. doi: 10.1161/CIRCEP.116.004609. Review.

PMID:
28213507
15.
16.
18.

Application and comparison of the FADES, MADIT, and SHFM-D risk models for risk stratification of prophylactic implantable cardioverter-defibrillator treatment.

van der Heijden AC, van Rees JB, Levy WC, van der Bom JG, Cannegieter SC, de Bie MK, van Erven L, Schalij MJ, Borleffs CJ.

Europace. 2017 Jan;19(1):72-80. doi: 10.1093/europace/euw005.

PMID:
28130376
19.

Long-Term Outcomes of Radio-Frequency Catheter Ablation on Ventricular Tachycardias Due to Arrhythmogenic Right Ventricular Cardiomyopathy: A Single Center Experience.

Wei W, Liao H, Xue Y, Fang X, Huang J, Liu Y, Deng H, Liang Y, Liao Z, Liu F, Lin W, Zhan X, Wu S.

PLoS One. 2017 Jan 25;12(1):e0169863. doi: 10.1371/journal.pone.0169863. eCollection 2017.

20.

The Design of the Understanding Outcomes with the S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED).

Gold MR, Knops R, Burke MC, Lambiase PD, Russo AM, Bongiorni MG, Deharo JC, Aasbo J, El Chami MF, Husby M, Carter N, Boersma L.

Pacing Clin Electrophysiol. 2017 Jan;40(1):1-8. doi: 10.1111/pace.12994. Epub 2017 Jan 15.

PMID:
27943348

Supplemental Content

Loading ...
Support Center